ASCO 2022 | RECIP: a novel framework for treatment response evaluation using PSMA-PET/CT in patients with mCRPC

PSMA-PET is a novel imaging technique for prostate cancer, demonstrating greater accuracy compared to conventional imaging such as CT, and recently gaining FDA approval for diagnostic purposes. Andrei Gafita, MD, University of California, Los Angeles, CA, talks on the development of RECIP, a novel framework for clinical treatment response assessment with PSMA-PET, to evaluate drug efficacy. First tested and developed via a cohort of patients treated with PSMA-targeted therapy, RECIP will be validated for drug efficacy with other treatment such as chemotherapy or hormonal treatment for prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.